Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Unknown2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06673628Phase 2Recruiting

Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

NCT04859465Phase 2UnknownPrimary

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

NCT03512834Phase 2UnknownPrimary

Paclitaxel-Avelumab for Angiosarcoma

Showing all 3 trials

Research Network

Activity Timeline